Stocklytics Platform
Asset logo for symbol NVAX
Novavax
NVAX65
$8.70arrow_drop_up0.46%$0.04
Asset logo for symbol NVAX
NVAX65

$8.70

arrow_drop_up0.46%

Income Statement (NVAX)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$118.09M$168.72M-$141.17M-$172.58M-$128.61M
EBITDA-$105.39M$179.86M-$129.03M-$161.79M-$117.29M
gross Profit$23.89M$379.44M$45.04M$142.46M-$76.86M
NET Income-$121.30M$162.38M-$147.55M-$178.38M-$130.77M
total Revenue$84.51M$415.48M$93.85M$291.34M$22.06M

Balance Sheet (NVAX)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$340.32M-$446.91M-$261.70M-$298.29M-$428.99M
stockholders Equity-$526.43M-$431.70M-$867.08M-$716.92M-$678.35M
total Assets$1.71B$1.81B$1.35B$1.85B$1.65B
total Debt$233.30M$233.24M$229.33M$280.63M$222.11M
total Liabilities$2.23B$2.25B$2.22B$2.57B$2.33B

Cash Flow (NVAX)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$97.00K$258.21M$5.88M$100.38M$197.12M
free Cash Flow-$145.56M$311.14M-$90.80M-$185.85M-$58.04M
investing Cash Flow-----$18.39M
operating Cash Flow-$144.81M$314.26M-$83.55M-$176.78M-$39.65M

Novavax (NVAX) Financials

Novavax Inc (NVAX) is a biotechnology company that specializes in the development of innovative vaccines to prevent infectious diseases. The company's financials provide valuable insights into its performance, profitability, and financial standing. The income statement shows Novavax's revenue and expenses, ultimately leading to its net income. The company's ebit (earnings before interest and taxes) and ebitda (earnings before interest, taxes, depreciation, and amortization) indicate its operating profitability and ability to generate cash flow from operations. Novavax's gross profit reflects the difference between its revenue and cost of goods sold, highlighting its manufacturing efficiency. The net income from stockholders represents the portion of profit attributable to shareholders after accounting for all expenses and taxes. Novavax's total revenue encompasses all sources of income, including product sales, collaborations, and grants.
Novavax's balance sheet provides a snapshot of the company's financial position at a specific point in time. It shows the value of Novavax's assets, including cash equivalents, investments, and property, plant, and equipment. The net debt represents the company's total debt minus its cash and cash equivalents, providing an indicator of its overall debt burden. Stockholders' equity represents the value of the company attributable to its shareholders, calculated by subtracting total liabilities from total assets. Novavax's total assets encompass all tangible and intangible resources it owns, while total debt includes both short-term and long-term liabilities. The cash flow statement illustrates how cash is generated and used by Novavax. It includes operating cash flow, which measures cash generated from core business operations, and investing cash flow, which reflects cash used for investments such as acquisitions or capital expenditures. Financing cash flow indicates cash flows from activities such as issuing or repurchasing stock and paying dividends. Lastly, free cash flow is the cash remaining after deducting capital expenditures from operating cash flow, representing the amount available for strategic investments or debt reduction.
In conclusion, Novavax Inc's financials provide a comprehensive overview of its financial performance and position. These metrics assist investors and stakeholders in assessing the company's profitability, operational efficiency, and ability to meet financial obligations. By analyzing Novavax's income statement, balance sheet, cash flow statement, and other relevant financial information, interested parties can make informed decisions regarding their investment in the company.
add Novavax  to watchlist

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level